Quidel to Present at Upcoming Conferences
November 10 2020 - 6:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the following upcoming conferences:
- Canaccord Genuity Virtual MedTech & Diagnostics
Forum on Thursday, November 19, 2020 at 1:30 p.m. Eastern Time
(10:30 a.m. Pacific Time).
- Piper Sandler 32nd Annual Virtual Healthcare Conference
on Wednesday, December 2, 2020 at 2:30 p.m. Eastern Time (11:30
a.m. Pacific Time).
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on the specified
days with question-and-answer sessions scheduled immediately
following each presentation. During the presentations, the company
will discuss business and financial developments and trends. The
company's statements may contain or constitute material information
that has not been previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the links below.
Canaccord: https://wsw.com/webcast/canaccord44/qdel/2435684
Piper Sandler:
https://wsw.com/webcast/pipersandler25/qdel/2901216
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 30 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, COVID-19, influenza,
respiratory syncytial virus, Strep A, lyme, herpes, pregnancy,
thyroid disease and fecal occult blood. Quidel's Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio and
to explore exciting employment opportunities, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201110006237/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024